Letters to the Editor

Comparative study of clinical efficacy with amitriptyline, pregabalin, and amitriptyline plus pregabalin combination in postherpetic neuralgia

Sir,

The most common and most intractable sequel of herpes zoster is postherpetic neuralgia (PHN). There is no universally accepted definition of postherpetic neuralgia. The duration of PHN was evaluated by using two definitions: Pain that persisted after healing of rash and pain that persisted for more than 30 days from the time of enrollment.[1] Some authors also described PHN as pain persisting for at least three months after healing of rash.[2] The overall incidence of PHN is 8 to 15%, using the first two definitions. Patients of age 50 years or older had a 14.7-fold higher prevalence of pain, 30 days after onset of rash, than patients younger than 50 years of age.[3] PHN is thought to be due to nerve damage caused by the varicella virus.

Many patients, however, are refractory to these treatments because of inadequate pain relief or intolerable side effects. The objective of the present study is to see the comparative clinical efficacy with monotherapy, either with amitriptyline or pregabalin and combined therapy with amitriptyline plus pregabalin.

A randomized comparative study of the clinical efficacy in PHN patients with the following treatment—amitriptyline, pregabalin, and amitriptyline plus pregabalin combination was carried...
Letters to the Editor

out in the Midnapore Medical College and Hospital. Inclusion criteria were as follows: (1) PHN of more than one month duration (2) pain at least moderately severe (disagreeable, unpleasant, uncomfortable) (3) patients aged 40 years or older and not pregnant. Patients with history of serious illness were excluded.

Patients were randomized into three groups comprising of 15 patients per group. Amitriptyline 25 mg was given once daily at night and pregabalin 75 mg twice daily. For the combined therapy group, both the medicines were given at the same doses.

Total period of study was eight weeks and the study was conducted from April 2008 to September 2008. The patients were reviewed after the second, fourth, and eighth weeks, to see the degree of improvement of pain perception and to check for any adverse reactions. Pain relief was assessed with a percentage rating, with patients being asked to estimate on a scale of 0 to 100%, how much better they were.

We considered it a satisfactory improvement if there was >50% improvement of pain perception after four weeks and >75% improvement after eight weeks of treatment. The differences of clinical efficacy of the three different groups were compared using the chi-square test.

A total of 45 patients with PHN were included in the study. They were randomized into three groups (i) amitriptyline (n = 15), (ii) pregabalin (n = 15), and (iii) amitriptyline plus pregabalin (n = 15).

Thirty males (66.7%) and 15 females (33.3%) participated in the present study.

Statistically, no significant differences in satisfactory improvement were seen in any group at the end of four weeks ($\chi^2 = 1.56$ and $P$ value = $>0.05$). At the end of eight weeks, statistically significant satisfactory improvement ($>75\%$) in pain perception was noticed in the combined group, with amitriptyline plus pregabalin, compared to the monotherapy groups, with either amitriptyline alone or only pregabalin ($\chi^2 = 11.23$ and $P$ value = $<0.05$) [Table 1]

<table>
<thead>
<tr>
<th>Therapy group</th>
<th>≥75% improvement (%)</th>
<th>≤75% improvement (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amitriptyline</td>
<td>2 (13.4)</td>
<td>13 (86.6)</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>8 (53.3)</td>
<td>7 (46.7)</td>
</tr>
<tr>
<td>Amitriptyline plus</td>
<td>11 (73.3)</td>
<td>4 (26.7)</td>
</tr>
<tr>
<td>pregabalin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dryness of the mouth was the most common adverse reaction in the amitriptyline group (7/15), drowsiness and dizziness in the pregabalin group (4/15 in each) and dizziness and dryness in combined group (5/15 in each). Intensity of these adverse reactions was mild-to-moderate and no patient stopped treatment due to adverse reactions.

The present study demonstrates that the combination therapy is more efficacious in relieving pain, compared to monotherapy, in patients with PHN, at the end of eight weeks of treatment.

Various studies with amitriptyline, nortriptyline or desipramine to placebo showed significant benefit when associated with tricyclic antidepressant therapy.[4] Two parallel group placebo-controlled trials in which the analgesic efficacy of pregabalin was investigated, showed superiority over placebo.[5] However, there is no study that compares combination therapy with monotherapy like the present study.

The present study shows that combination therapy reduces the perception of pain sensation significantly compared to monotherapy. The side effects of the combination therapy are almost the same as for monotherapy. Therefore, we concluded that in a PHN patient, a combination therapy with amitriptyline or pregabalin, may be more beneficial than monotherapy, after completion of eight weeks of treatment.

Arun Achar1, Gobinda Chatterjee2, Tapobrata Guha Ray, Biswanath Naskar3

Departments of Community Medicine, Dermatology1, Midnapore Medical College, Midnapore, West Bengal, India

Address for correspondence: Dr. Arun Achar, D-2, Burge Town, P.O-Midnapore, Dist. - Paschim Medinipur, West Bengal - 721 101, India
E-mail: achararun@rediffmail.com

DOI: 10.4103/0378-6323.58686 - PMID: 20061738

REFERENCES

A rare association of acanthosis nigricans with Crouzon syndrome

A 5-year-old male child was presented in the ophthalmology outpatient department (OPD) with ocular complications in early childhood. The child was apparently normal at birth. The mother noticed a gradual bulging of the left eye after 3-4 weeks of birth. Gradually, there was expulsion of the left eye of 3-4 months. When the child was 5-6 months old, she noticed a similar gradual bulging of the child's right eye. The patient was referred to the dermatology OPD for skin changes. There was no history of consanguinity of marriage in the parents. No history of similar disorder in the family. There was also no history of consanguinity and history of consanguinity and mood disturbances in patients with postherpetic neuralgia: Results of a randomized, placebo-controlled clinical trial. Pain 2004;109:26-35.

Acanthosis nigricans is a feature of several syndromes caused by active mutations of the FGFR2. Acanthosis nigricans is assumed to be a rare abnormality. Although the true frequency is uncertain, some estimate that acanthosis nigricans is associated with 5% of all Crouzon cases of Crouzon syndrome with acanthosis nigricans is a different entity from the classic Crouzon syndrome. These include rare Crouzon syndrome, described in the medical literature, had been reported in the medical literature. Because according to Friedhofer in 2006, only 30 cases of Crouzon syndrome with acanthosis nigricans, thanatophoric dysplasia, severe achondroplasia with developmental delay and SADDAN syndrome. These data support the view that the association of Crouzon syndrome with acanthosis nigricans, thanatophoric dysplasia, severe achondroplasia with developmental delay and SADDAN syndrome. These data support the view that the association of Crouzon syndrome with acanthosis nigricans is noted in the (FGFR2) gene. Acanthosis nigricans can coexist with Crouzon syndrome was described in 1912 as one of the varieties of craniofacial dysostoses caused by administration of a new treatment. But, here, the mutation is noted in the fibroblast growth factor receptor-2 (FGFR2) gene. Acanthosis nigricans can coexist with Crouzon syndrome. But, here, mutation is noted in the fibroblast growth factor receptor-2 (FGFR2) gene.

But, the sagittal suture lines did not fuse. The right fontanelle. Craniosynostosis was seen with premature fusion of metopic, coronal and lamboid sutures. The disproportion between craniostenosis and brain growing may lead to death at a very early age. Early prenatal diagnosis can aid in diagnostic, therapeutic and further management in women who want to continue with pregnancy. Ultrasound in combination with medical history can be used to diagnose Crouzon syndrome. But, there are cases due to variable expressions, history of consanguinity and mutation in the FGFR2 gene. Acanthosis nigricans can coexist with Crouzon syndrome. But, here, mutation is noted in the fibroblast growth factor receptor-2 (FGFR2) gene.

The child was apparently normal at birth. The mother noticed a gradual bulging of the child's right eye. The patient was referred to the dermatology OPD for skin changes. There was no history of consanguinity of marriage in the parents. No history of similar disorder in the family. There was also no history of consanguinity and mood disturbances in patients with postherpetic neuralgia: Results of a randomized, placebo-controlled clinical trial. Pain 2004;109:26-35.

But, there are cases due to variable expressions, history of consanguinity and mutation in the FGFR2 gene. Acanthosis nigricans can coexist with Crouzon syndrome. But, here, mutation is noted in the fibroblast growth factor receptor-2 (FGFR2) gene. Acanthosis nigricans can coexist with Crouzon syndrome. But, here, mutation is noted in the fibroblast growth factor receptor-2 (FGFR2) gene.
Be on the top with Lumenis

**Only company with direct presence in India**

Best in class Lasers: LightSheer and Ultrapulse

Strong Service Network in India

Comprehensive clinical trainings from renowned clinicians

Strong Base of Users in India

For more information please contact:

Lumenis India Pvt. Ltd., 308-309-310, 3rd Floor, Suncity Business Tower, Golf Course Road, Sector -54, Gurgaon - 122 002 Haryana, India. Tel: +91-1244854902; M: +91-8800411599, Fax: +91-1244854932

Email: shantanu.bhatnagar@lumenis.com

India Service Helpline: 0124-4210795, Email: customercareindia@lumenis.com